Grand River Aseptic Manufacturing (GRAM), a leading parenteral contract manufacturing organization, is expanding its capabilities in syringe filling at its FDA-inspected, cGMP-compliant manufacturing facility in Grand Rapids, MI with the Colanar FSV syringe filler. 

The Colanar FSV syringe filler will utilize the existing single-use systems already in place at GRAM and will support both small molecule APIs and biologics projects. The purchase, the company says, is one of many capital investments being made to support client growth and enhance its capabilities. 

The purchase of the syringe filler comes only months after the news of a partnership deal reached between GRAM and Arlington Capital Partners, a private equity firm based in Washington, D.C. 

“With the support of Arlington, GRAM intends to invest heavily in building out our capabilities in the next couple of years with state-of-the-art equipment and a new facility. The new syringe filler is the first of many exciting announcements we will be making this year,” said Tom Ross, president and chief executive officer of GRAM. 

“The new syringe filler will expand our capabilities and demonstrates GRAM’s commitment to quality while advancing our core capabilities and technology,” said Steve Nole, director of operations, GRAM. “The Colonar FSV syringe filler, combined with our single-use system, will allow clients to expedite the time between project initiation and manufacture date.” 

The syringe filler will be qualified and operational by the second quarter of this year. In addition to filling syringes, the new filler is capable of handling cartridges.